Role of Proteinase-Activated Receptors in Brain Function
Publisher
Springer-Verlag
Reference191 articles.
1. Ahn HS, Chackalamannil S, Boykow G, Graziano MP, Foster C, 2003, Development of proteinase-activated receptor 1 antagonists as therapeutic agents for thrombosis, restenosis and inflammatory diseases. Curr Pharm Des. 9: 2349–2365. 2. Akassoglou K, Adams RA, Bauer J, Mercado P, Tseveleki V, Lassmann H, Probert L, Strickland S, 2004, Fibrin depletion decreases inflammation and delays the onset of demyelination in a tumor necrosis factor transgenic mouse model for multiple sclerosis. Proc Natl Acad Sci USA. 101: 6698–6703. 3. Anderluh M., and Dolenc MS, 2002, Thrombin receptor antagonists; recent advances in PAR-1 antagonist development. Curr Med Chem. 9: 1229–1250. 4. Asfaha S, Brussee V, Chapman K, Zochodne DW, and Vergnolle N, 2002, Proteinaseactivated receptor-1 agonists attenuate nociception in response to noxious stimuli. Br J Pharmacol. 135: 1101–1106. 5. Asokananthan N, Graham PT, Fink J, Knight DA, Bakker AJ, McWilliam AS, Thompson PJ, and Stewart GA, 2002, Activation of protease-activated receptor (PAR)-1, PAR-2, and PAR-4 stimulates IL-6, IL-8, and prostaglandin E2 release from human respiratory epithelial cells. J Immunol. 168: 3577–3585.
|
|